MeiraGTx reports 2021 net loss of $79.6M; cash $137.7M; pipeline advances

MeiraGTx Holdings plc

Net loss $79.6M ($1.80/share) vs $58.0M ($1.54/share) in 2020; license revenue rose to $37.7M from $15.6M.
Cash and equivalents $137.7M at Dec 31, 2021; expects to fund operations through Q2 2023.
Phase 3 Lumeos trial for XLRP enrolling; received $30M milestone from Janssen.
Positive Phase 1 data for AAV-hAQP1 in xerostomia; Phase 2 start planned by end of 2022.
R&D expenses $67.1M vs $33.9M, driven by ophthalmology, neurology, and manufacturing programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.